WaveMan
WaveMan · Company
CLNN · Clene Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

CLNN Clene (CLNN) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001822791
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
15
13F, latest reported quarter

What the filings say about CLNN

Insiders, 180 days
-$1.2M net sold
1 seller · 0% of sales under a 10b5-1 plan

Clene insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Clene Inc. insiders sold a net $1.2M of stock across 124 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Ugwumba Chidozie
SELL
2026-05-13 SECtraded 2026-05-12
73,296
$454.4K
-45.5%
Context
  • 63 earlier Form 4 trades (code P or S) here by this insider (2 buys, 61 sales), the last on May 11, 2026.
  • +8.9% median (+8.9% mean) 90-day return after 2 previous buys.
  • The trade is 70.9% of the 103,417 shares held after it.
  • No other insider sold within 30 days.
  • 15 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Ugwumba Chidozie sold about $454.4K of CLNN on May 12, 2026; 15 funds added in the latest 13F quarter.
Ugwumba Chidozie
SELL
2026-05-13 SECtraded 2026-05-11
22,177
$149.7K
-45.5%
Context
  • 62 earlier Form 4 trades (code P or S) here by this insider (2 buys, 60 sales), the last on May 4, 2026.
  • +8.9% median (+8.9% mean) 90-day return after 2 previous buys.
  • The trade is 12.5% of the 176,713 shares held after it.
  • No other insider sold within 30 days.
  • 15 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Ugwumba Chidozie sold about $149.7K of CLNN on May 11, 2026; 15 funds added in the latest 13F quarter.
Ugwumba Chidozie
SELL
2026-05-05 SECtraded 2026-05-04
72,884
$495.6K
-46.4%
Context
  • 61 earlier Form 4 trades (code P or S) here by this insider (2 buys, 59 sales), the last on May 1, 2026.
  • +8.9% median (+8.9% mean) 90-day return after 2 previous buys.
  • The trade is 36.6% of the 198,890 shares held after it.
  • No other insider sold within 30 days.
  • 15 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Ugwumba Chidozie sold about $495.6K of CLNN on May 4, 2026, the largest insider sale at the company on our record; 15 funds added in the latest 13F quarter.
Ugwumba Chidozie
SELL
2026-05-05 SECtraded 2026-05-01
5,795
$34.8K
-46.4%
Context
  • 60 earlier Form 4 trades (code P or S) here by this insider (2 buys, 58 sales), the last on Apr 30, 2026.
  • +8.9% median (+8.9% mean) 90-day return after 2 previous buys.
  • The trade is 2.1% of the 271,774 shares held after it.
  • No other insider sold within 30 days.
  • 15 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Ugwumba Chidozie sold about $34.8K of CLNN on May 1, 2026; 15 funds added in the latest 13F quarter.
Ugwumba Chidozie
SELL
2026-04-30 SEC
5,736
$34.9K
-37.5%
Context
  • 59 earlier Form 4 trades (code P or S) here by this insider (2 buys, 57 sales), the last on Apr 29, 2026.
  • +8.9% median (+8.9% mean) 90-day return after 2 previous buys.
  • The trade is 2.1% of the 277,569 shares held after it.
  • No other insider sold within 30 days.
  • 15 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Ugwumba Chidozie sold about $34.9K of CLNN on Apr 30, 2026; 15 funds added in the latest 13F quarter.
124 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 119 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$1.2M over 180 days
-$1.2M of it by a 10%+ holder
below 64% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
15 funds bought in last quarter
below 73% of Pharma & Biotech
Revenue
-41.5% year over year
below 78% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
8.4% of the float short (float per yahoo 2026-10-26) · 7.5 days to cover · settled 2026-09-30
more than 60% of Pharma & Biotech
What changed in the last 30 days
Oct 28Insider selling stopped: no sales in 90 days after 3 in the prior 90
Why it matters
The absence is the signal: 3 sales in one 90-day window and none in the next is a change of behaviour, not a filing.

Watch CLNN

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-52.9%12M
-62%-24%+15%+53%2025-102025-122026-022026-042026-062026-082026-10 2026-05-04 · Ugwumba Chidozie sold $495.6K2025-12-04 · Ugwumba Chidozie sold $489.6K2026-05-12 · Ugwumba Chidozie sold $454.4K2025-12-03 · Ugwumba Chidozie sold $444.7K2026-04-21 · Ugwumba Chidozie sold $376.7K2026-03-31 · Ugwumba Chidozie sold $331.8K2025-12-05 · Ugwumba Chidozie sold $221.2K2026-01-13 · MATLIN DAVID J bought $216.7K2026-01-12 · Ugwumba Chidozie sold $179.9K2026-04-17 · Ugwumba Chidozie sold $161.0K2026-05-11 · Ugwumba Chidozie sold $149.7K2026-01-13 · Ugwumba Chidozie sold $127.7K2025-12-08 · Ugwumba Chidozie sold $122.3K2026-04-02 · Ugwumba Chidozie sold $119.9K2026-01-14 · Ugwumba Chidozie sold $100.5K2025-12-09 · Ugwumba Chidozie sold $89.4K2026-03-27 · Ugwumba Chidozie sold $83.0K2026-03-30 · Ugwumba Chidozie sold $79.2K2025-12-31 · Ugwumba Chidozie sold $76.1K2025-12-11 · Ugwumba Chidozie sold $74.3K2025-12-15 · Ugwumba Chidozie sold $68.7K2026-04-29 · Ugwumba Chidozie sold $68.5K2026-01-22 · Ugwumba Chidozie sold $67.4K2026-01-29 · Ugwumba Chidozie sold $66.0K2026-01-15 · Ugwumba Chidozie sold $64.1K2025-12-10 · Ugwumba Chidozie sold $63.7K2026-01-21 · Ugwumba Chidozie sold $61.2K2026-01-20 · Ugwumba Chidozie sold $59.7K2026-01-09 · Ugwumba Chidozie sold $56.9K2025-12-12 · Ugwumba Chidozie sold $51.6K2026-04-16 · Ugwumba Chidozie sold $49.6K2025-12-29 · Ugwumba Chidozie sold $48.2K2025-12-16 · Ugwumba Chidozie sold $44.4K2025-12-23 · Ugwumba Chidozie sold $42.8K2026-01-28 · Ugwumba Chidozie sold $42.8K2026-04-15 · Ugwumba Chidozie sold $41.3K2026-01-16 · Ugwumba Chidozie sold $40.6K2026-03-25 · Ugwumba Chidozie sold $39.0K2025-12-18 · Ugwumba Chidozie sold $36.8K2025-12-19 · Ugwumba Chidozie sold $36.0K2026-04-30 · Ugwumba Chidozie sold $34.9K2026-05-01 · Ugwumba Chidozie sold $34.8K
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns CLNN: institutional holders (13F)

13F holdings, latest reported quarter
Empery Asset Management, LP
916,532 sh
$5.6M
SCOGGIN MANAGEMENT LP
600,000 sh
$3.7M
Boxer Capital Management, LLC
477,515 sh
$2.9M
Ensign Peak Advisors, Inc
348,062 sh
$2.1M
VANGUARD CAPITAL MANAGEMENT LLC
333,706 sh
$2.1M

Congress trades in CLNN

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

CLNN planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

CLNN mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Micro-Cap ETF
$160.2K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$10.6K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$301.9K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$613.0K position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$48.6K position · as of 2026-05-31
0.0%
Total Stock Market Index Trust
$1.6K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $1.2M sold by insiders over 180 days, 15 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

CLNN financials

Revenue growth
-41.5%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$197.0K
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
-$15.9M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Cash flow to debt
-0.90x
TTM operating cash flow over LongTermDebt as filed 2026-06-30 (includes the current portion)
Return on equity
n/a
average equity is zero or negative
Return on assets
-175.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-125.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Enterprise value
$57.3M
market value at close 2026-10-26 on 2026-08-11 shares, plus LongTermDebt as filed 2026-06-30 (includes the current portion), minus cash 2026-06-30
FCF yield
-32.3%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$200.0K$342.0K$654.0K$473.0K
Operating income-$23.1M-$33.1M-$40.5M-$48.4M
Net income-$26.2M-$39.4M-$49.5M-$29.9M
Operating cash flow-$18.5M-$21.3M-$30.2M-$39.0M
Cash$5.2M$12.2M$28.8M$18.3M
Long-term debt$17.8M$10.8M$5.3Mn/a
SEC XBRL, fiscal years, as known on 2026-10-28

CLNN Stock Sonar score 6/7 axes

Find similar shapesCompare

CLNN ranks highest on risk and compliance (70th percentile) and financial health (54th), and lowest on profitability (16th), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
16
Inputs
  • Return on equityaverage equity is zero or negative
  • Return on assets-175.0% · 13 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-125.5% · 19 pct, sector of 576
Financial health
54
Inputs
  • Debt to equityequity is zero or negative, the ratio has no meaning
  • Cash flow to debt-0.90x · 54 pct, sector of 371
Growth
22
Inputs
  • Revenue growth, YoY-41.5% · 22 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
17
Inputs
  • Net Form 4 buying (codes P and S), 180d-$1.2M · 34 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
27
Inputs
  • Funds adding, latest quarter15 · 27 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
70
Inputs
  • Short interest, % of float+8.4% · 45 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+2.3% · 94 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

CLNN filings, in plain words

Are Clene insiders buying or selling CLNN?

In the 180 days to 2026-10-28, Clene insiders were net sellers, a net $1.2M across purchases and sales reported on Form 4, by 1 seller.

Read the full summary

In the 180 days to 2026-10-28, Clene insiders were net sellers of CLNN, a net $1.2M across purchases and sales reported on Form 4 by 1 seller. Most of that figure, $1.2M, came from a holder of 10% or more rather than an officer or director. None of the 4 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies